| Name | Title | Contact Details |
|---|
Myspace is a leading social entertainment destination powered by the passions of fans.
MyPypeline is a Vancouver, BC-based company in the Software and Internet sector.
From planning and documentation to billing and beyond, Radformation`s user-friendly, FDA-cleared tools seamlessly integrate into your workflow to increase quality and efficiency in all stages of the treatment planning process. ClearCheck, our automated plan check and documentation software, ensures the highest quality treatment plans and helps clinics save time with 80+ plan checks and instant documentation. ClearCalc, our independent calculation software, efficiently validates plan accuracy, providing instant dose validation of photon, brachytherapy, and electron plans. EZFluence automatically generates high-quality 3D plans in just one click—for any beam arrangement and any treatment site from head to toe. AutoContour, our fast and accurate automated AI contouring software, automatically segments 50 of the most commonly delineated clinical structures in seconds. ChartCheck, our treatment evaluation software, actively monitors patient data in real-time to ensure safety for ongoing treatments. QuickCode billing QA software instantly evaluates charges, automatically catching missed or incorrect codes and ensuring appropriate compensation. Save time and resources while increasing quality and safety with Radformation.
TrafficCast is a Madison, WI-based company in the Software and Internet sector.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.